Use of Low‐Density Lipoprotein–Lowering Therapies Before and After PCSK9 Inhibitor Initiation

摘要

Proprotein convertase subtilisin/kexin type 9 inhibitors ( 9i) are used to reduce low‐density lipoprotein ( ) cholesterol. 9i use after initiation, as well as persistence with or alterations to other ‐lowering therapy after 9i initiation, is not well understood.